At a glance
ClinicalIndex Comparison RecordN/ACompleted· 5,745 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effectiveness and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
In Brief
An observational study for Rheumatoid Arthritis. Completed, enrolled 5,745 participants across 370 sites.
Detailed Summary
Observation of safety, tolerability and effectiveness of adalimumab (Humira) therapy in a large patient collective under everyday clinical conditions over a 5-year period.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2003
First PostedMar 2010
Primary CompletionMar 2013
TodayJul 2026
First PostedMar 2, 2010
Enrollment StartApr 1, 2003
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 9.9 yearsPosted 16.3 years ago